newsfilter
← Latest News
ACCESS Newswire·

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer , with clinical study expected to begin H2 2025; Clinical Trial Application filed in